Therefore, the present study aimed to investigate whether switching to dulaglutide, a weekly injectable GLP-1 receptor agonist, from insulin improves glycemic control in patients with T2D inadequately controlled with conventional insulin treatment. Here, GLP1R is linked to type 2 diabetes mellitus.